enzh-TWfrdeitjaptrues

Your privacy is important to us, so we operate the site by the following principles:

Confidentiality
You may use our site without disclosing personally identifiable information. We want to be clear that we will not obtain such information about you unless you choose to submit it to us. If you supply personally identifiable information (such as name, address or telephone numbers) for various purposes on this site, we only use the information for that purpose (such as to provide the service or information you have requested).

Security
The Dana-Farber Waldenstrom's Macroglobulinemia Program takes every precaution to protect our users' information. When a registration/order form asks users to enter sensitive information (such as credit card number and/or diagnosis), that information is encrypted and is protected with the best encryption software in the industry- SSL.

Should you electronically request a referral to a Dana-Farber physician, we will use the information you submit to arrange for care where appropriate. While we use SSL encryption to protect sensitive information online, we also do everything in our power to protect user-information off line. Our software and hardware is configured to provide maximum security.

To use our contact form, the Magic Word is Bing.

Cookies
The Dana-Farber Waldenstrom's Macroglobulinemia Program Web sites use cookies to track traffic coming to our site. We do not collect personal data such as name, age, phone number, e-mail, or mailing address. Cookies will also be used to identify a person who chooses to register on our site. If you choose to register on our site and are given a password for an event, give donations on line, or choose to enroll in our e-mail subscription services, we will identify you with cookies. You will always have a chance to opt out at any time.

Information Collection and Use
The Dana-Farber Waldenstrom's Macroglobulinemia Program is the sole owner of the personal medical information collected on this site. We will not sell, share, or rent this information to others. The Dana-Farber occasionally trades its contributor mailing lists with other non-profit organizations. This process saves us money and is carefully monitored and one may always opt-out.

Donations on the Web
When you make a gift on our site, your e-mail will be entered into our donor database. We may send you e-mails or mailings in the future informing you of other giving opportunities or providing news about The Dana-Farber Bing Center for Waldenstrom's Macroglobulinemia. If you choose not to receive any further communication from us, you may opt-out by e-mailing This email address is being protected from spambots. You need JavaScript enabled to view it. or calling our offices at 1-617-632-6285.

Latest Bing Center News

Infection Prevention Strategies for Waldenstrom's Macroglobulinemia

Infection Prevention Strategies for Waldenstrom's Macroglobulinemia

This video webinar was presented by Dr. Andrew Branagan on September 15, 2021 as part of the IWMF's ongoing series of Ed Forum Workshops.

Read more..

When Should a Patient Seek Treatment for Waldenstrom Macroglobulinemia?

When Should a Patient Seek Treatment for Waldenstrom Macroglobulinemia?

Approximately 30% of Waldenstrom macroglobulinemia patients are advised to "watch and wait" at time of diagnosis. When should a patient seek treatment?

Read more..

Timely Updates in the Treatment of Waldenstrom's Macroglobulinemia

Timely Updates in the Treatment of Waldenstrom's Macroglobulinemia

As a follow-up to our recent announcement regarding the FDA approval of Zanabrutinib for the treatment of Waldenstrom's Macroglobulinemia (Sept 2, 2021), we are pleased to share this lecture, presented as a webinar on September 24, 2021 by Dr. Steven Treon.

Read more..

Newsweek Names Dana-Farber #3 in the World for Cancer

Newsweek Names Dana-Farber #3 in the World for Cancer

Dana-Farber has been named one of the world’s best cancer hospitals by Newsweek in its new World’s Best Specialized Hospitals 2022 rankings. Dana-Farber was ranked #3 globally. We are the only hospital in New England to be ranked in the top 15 for oncology.

Read more..

FDA Approves Zanubrutinib for the Treatment of Waldenströms Macroglobulinemia

FDA Approves Zanubrutinib for the Treatment of Waldenströms Macroglobulinemia

“The ASPEN trial provided compelling evidence that Brukinsa is a highly active BTK inhibitor in Waldenström’s macroglobulinemia, and compared to the first-generation BTK inhibitor, showed improved tolerability across a number of clinically important side effects. The approval of BRUKINSA provides an important new option for targeted therapy in Waldenström’s macroglobulinemia,” Steven Treon, MD, PhD, director of the Bing Center for Waldenström’s Macroglobulinemia Research at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School, said in a statement.

Read more..

LLS National Blood Cancer Conference, September 18, 2021

LLS National Blood Cancer Conference, September 18, 2021

This Blood Cancer Conference is one of many programs developed by The Leukemia & Lymphoma Society to meet the needs of patients, survivors, families and oncology professionals, the people who deal with blood cancer every day and the people who care for them. BCC attendees receive the most current information and access to local resources to help navigate and make informed decisions about their treatment and survivorship.

Read more..

18th International Myeloma Workshop, September 8-11, 2021

18th International Myeloma Workshop, September 8-11, 2021

The International Myeloma Workshop is the defining annual meeting in myeloma with a focus on both the basic, preclinical and the clinical aspects, including: Scientific Programs, Oral Presentations (on Basic Biology, Preclinical Trials and Clinical Studies), Consensus Panels, Poster Presentations.

Read more..

NCCN Guidelines Add Zanubrutinib as Preferred Therapy for Waldenström Macroglobulinemia

NCCN Guidelines Add Zanubrutinib as Preferred Therapy for Waldenström Macroglobulinemia

The NCCN Guidelines Version 1.2022 Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma (WM/LPL) were updated to include zanubrutinib as a preferred regimen for the primary therapy of WM/LPL along with bendamustine/rituximab, bortezomib/dexamethasone/rituximab, ibrutinib ± rituximab, and rituximab/cyclophosphamide/dexamethasone. Preferred interventions are based on superior efficacy, safety, and evidence.

Read more..

The 300 Project forges ahead with Bliss gift

The 300 Project forges ahead with Bliss gift

“We are looking at how cancer cells from patients who may not seem connected clinically may be utilizing the same networks through different mechanisms,” explains Zachary Hunter, PhD, one of the project’s leaders.

Read more..

A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies

A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies

This article reviews the pharmacology, clinical efficacy, safety, dosing, drug-drug interactions, and implications for advanced practitioners of BTK inhibitors in the treatment of B-cell malignancies.

Read more..